(Source: Datamonitor)
AstraZeneca, a UK-based pharmaceutical company, has reported a net income of $2.12 billion, or $1.46 per diluted share, for the third quarter ended September 30, 2009, compared to $1.74 billion, or $1.19 per diluted share, for the third quarter ended September 30, 2008.
Total revenues were $8.2 billion for the third quarter of 2009, compared to $7.8 billion for the same quarter of 2008.
Net income for the nine months ended September 30, 2009 was $5.98 billion, or $4.12 per diluted share, compared to $4.88 billion, or $3.33 per share, for the nine months ended September 30, 2008.
Total revenues were $23.86 billion for the nine months ended September 30, 2009, compared to $23.41 billion, for the prior-year period.
David Brennan, CEO of AstraZeneca, said: "Our strong business performance is driven by good operating execution bolstered by revenue upsides from Toprol-XL and H1N1 vaccine sales. All these factors are reflected in our results for the first nine months and our increased core EPS target for the full year.
"Since the half year we have made progress on the pipeline with the approval of Onglyza, the European submission for Brilinta and new external collaborations, tempered by the disappointing news on Zactima."
A service of YellowBrix, Inc.
